PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.68%
Revenue growth at 50-75% of 3141.T's 8.64%. Martin Whitman would worry about competitiveness or product relevance.
7.34%
Gross profit growth under 50% of 3141.T's 15.19%. Michael Burry would be concerned about a severe competitive disadvantage.
14.18%
EBIT growth below 50% of 3141.T's 86.48%. Michael Burry would suspect deeper competitive or cost structure issues.
14.18%
Operating income growth under 50% of 3141.T's 168.40%. Michael Burry would be concerned about deeper cost or sales issues.
28.60%
Net income growth at 75-90% of 3141.T's 33.41%. Bill Ackman would press for improvements to catch or surpass competitor performance.
28.61%
EPS growth at 75-90% of 3141.T's 33.91%. Bill Ackman would push for improved profitability or share repurchases to catch up.
28.61%
Diluted EPS growth at 75-90% of 3141.T's 33.91%. Bill Ackman would expect further improvements in net income or share count reduction.
-0.00%
Share reduction while 3141.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3141.T is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
28.80%
10Y revenue/share CAGR under 50% of 3141.T's 166.77%. Michael Burry would suspect a lasting competitive disadvantage.
48.70%
5Y revenue/share CAGR at 50-75% of 3141.T's 69.57%. Martin Whitman would worry about a lagging mid-term growth trajectory.
22.33%
3Y revenue/share CAGR at 50-75% of 3141.T's 34.95%. Martin Whitman would question if the firm lags behind competitor innovations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.58%
Below 50% of 3141.T's 222.35%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
18.88%
Below 50% of 3141.T's 50.75%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
12.08%
Below 50% of 3141.T's 45.11%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
161.83%
10Y equity/share CAGR at 50-75% of 3141.T's 272.26%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
104.73%
5Y equity/share CAGR 1.25-1.5x 3141.T's 73.67%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
50.85%
3Y equity/share CAGR 1.25-1.5x 3141.T's 41.10%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
81.82%
Below 50% of 3141.T's 500.00%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
77.78%
5Y dividend/share CAGR at 75-90% of 3141.T's 87.50%. Bill Ackman wants more robust earnings or a higher payout ratio to match the competitor.
45.45%
3Y dividend/share CAGR similar to 3141.T's 42.86%. Walter Schloss finds parallel short-term dividend strategies for both companies.
43.48%
AR growth well above 3141.T's 2.58%. Michael Burry fears inflated revenue or higher default risk in the near future.
3.24%
Inventory growth well above 3141.T's 1.17%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
5.71%
Similar asset growth to 3141.T's 5.98%. Walter Schloss finds parallel expansions or investment rates.
3.66%
50-75% of 3141.T's 5.98%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
111.10%
Debt growth far above 3141.T's 10.88%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-40.01%
We cut SG&A while 3141.T invests at 7.70%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.